Malvern, PA, United States
Malvern, PA, United States

Neuronetics is a privately held company developing non-invasive treatments for depression and other chronic psychiatric and neurological disorders based upon neuromodulation technology. The NeuroStar transcranial magnetic stimulation therapy system was developed for treating major depression in patients who have not benefitted from prior antidepressant medications.Neuronetics was founded within The Innovation Factory, an Atlanta, GA-based medical technology incubator. The Company has raised venture capital based on its intellectual property portfolio and management team. Neuronetics’ investors include life-sciences firms such as Quaker BioVentures, Three Arch Partners, Investor Growth Capital, Onset Ventures, Interwest Partners, KBL Healthcare Ventures, Accuitive Medical Ventures and New Leaf Venture Partners.On September 1, 2010, the World Economic Forum announced the company as a Technology Pioneer for 2011. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

"We are pleased to welcome Ascension Ventures as a new investor and are proud of the support we continue to receive from the venture capital firms that currently invest in NeuroStar," said Chris Thatcher, President and CEO of Neuronetics. "Investors continue to recognize the transformative work we are doing with NeuroStar Advanced Therapy in helping patients with Major Depressive Disorder, and see the broad potential in expanding access to this important therapy to the more than four million treatment-resistant adults living with depression who aren't currently benefiting from their current antidepressant treatment plans. With the recent launch of our next generation NeuroStar system and the broad-based support we are receiving from doctors, patients and insurance companies, the future is bright at Neuronetics." Neuronetics' Series G funding demonstrates the market's desire for innovative, effective and convenient treatment protocols for MDD. "We are confident Neuronetics will play an important role in how clinicians treat MDD in the future," said Rubal Bedi, Investment Director at Ascension Ventures. "Neuronetics offers an innovative treatment that is helping thousands of people achieve remission from depression. We are excited to support the management team of Neuronetics and believe accelerating the market adoption of NeuroStar Advanced Therapy is the right choice for patients and clinicians." In addition to its newest investor, Ascension Ventures, Neuronetics works with venture capital firms in the life sciences industry, including Accuitive Medical Ventures, GE Ventures, Interwest Partners, Industry Ventures, Investor Growth Capital, KBL Healthcare Ventures, New Leaf Venture Partners, Onset Ventures, Pfizer, Polaris Venture Partners and Three Arch Partners. All firms participated in the Series G financing. To learn more about Neuronetics, Inc. and NeuroStar Advanced Therapy, visit www.NeuroStar.com. About Neuronetics, Inc. Neuronetics, Inc. is a privately held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. Based in Malvern, PA, Neuronetics, Inc. is the leader in transcranial magnetic stimulation (TMS) with its development of NeuroStar® Advanced Therapy, a noninvasive form of neuromodulation. For more information, please visit www.neurostar.com. NeuroStar® is a registered trademark of Neuronetics, Inc. About Ascension Ventures Ascension Ventures (www.ascensionventures.org) is a strategic healthcare venture firm with four funds and more than $800 million in capital under management. The firm is a wholly owned subsidiary of Ascension, the nation's largest Catholic and non-profit health system. Ascension Ventures' role is to construct and manage a strategic portfolio of investments that deliver venture-level investment returns, have the potential to transform the healthcare industry, and significantly enhance the experience for patients, their families and their caregivers. Its health system limited partners operate 474 hospitals, have 578,000 employees and generate $88 billion in annual revenue. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neuronetics-inc-raises-15-million-in-series-g-equity-financing-led-by-ascension-ventures-300469405.html


Patent
Neuronetics | Date: 2017-04-12

Disclosed is a system for reducing discomfort caused by a magnetic stimulation device. The system comprises a stimulation circuit; a magnetic stimulation device configured to be driven by the stimulation circuit to create a pulsed magnetic field; a signal generator; a power source configured to provide power to the signal generator; and at least one conductor used with the magnetic stimulation device. The signal generator is configured to provide a signal to the at least one conductor to cause the at least one conductor to generate a second magnetic field.


Patent
Neuronetics | Date: 2013-11-11

A method, system, and apparatus for monitoring a magnetic field related to magnetic stimulation may be provided. A system for monitoring a pulsing magnetic field related to magnetic stimulation therapy may include a magnetic stimulation component, a sensor, and a processor. The magnetic stimulation component may be configured to generate the pulsing magnetic field for the magnetic stimulation therapy. The sensor may be configured to generate a signal associated with the pulsing magnetic field. The processor may be configured to estimate a first characteristic associated with a first peak of the signal, estimate a second characteristic associated with a second peak of the signal, and determine a third characteristic of the signal based on the first characteristic and the second characteristic. The processor may be configured to determine whether a failure occurred based on the third characteristic of the signal.


Patent
Neuronetics | Date: 2015-12-29

The inventive technique includes a system, method and device for treating a patient. The device includes a magnetic device having a core created by a binder process having a relatively low temperature. The device further includes a conductor in electrical communication with the core.


A TMS device may include treatment coils and ferromagnetic components that are configured to be disposed proximate to corresponding ones of the treatment coils. The treatment coils and ferromagnetic components of the TMS device may cooperatively generate a magnetic field that exhibits one or more characteristics that differ from those of a magnetic field that is generated by the treatment coils alone. For example, the magnetic field may exhibit lower induced electrical stimulation intensity in the cranial nerves, while substantially maintaining a penetration depth into the subjects brain. In another example, the magnetic field may exhibit increased penetration depth into the subjects brain, while substantially maintaining induced electrical stimulation intensity in the cranial nerves. The TMS device may be configured to be adjustable and/or reconfigurable, for instance with respect to the anatomy of a subject (e.g., to the shape of the subjects head).


Patent
Neuronetics | Date: 2015-02-10

A model of a human subjects head may be generated to assist in a therapeutic and/or diagnostic procedure. A treatment and/or diagnostic system may generate a fitted head model using a predetermined head model and a plurality of points. The plurality of points may include facial feature information and may be determined using a sensor, which may include an IR sensor. One or more anatomical landmarks may be determined and registered in association with the fitted head model using the facial feature information, for example, without the use of additional image information, such as an MRI image. The fitted head model may include visual aids, for example, anatomical landmarks, reference points, marking of the human subjects MT location, and/or marking of the human subjects treatment location. The visual aids may assist a technician to perform the therapeutic and/or diagnostic procedure of the human subject. The fitted head model may be stored.


Patent
Neuronetics | Date: 2013-07-10

The invention is directed to a novel method for reducing discomfort caused by transcutaneous stimulation. The novel method includes providing transcutaneous stimulation, reducing the transcutaneous stimulation at a first location, and substantially maintaining the transcutaneous stimulation at a second location. The transcutaneous stimulation may be created by electric and/or magnetic fields. The first location may be relatively proximate to the cutaneous surface and may comprise tissue, nerves and muscle. Also, the second location may be relatively deeper than the first location and include, for example, brain tissue that requires the transcutaneous stimulation for treatment purposes. The invention further may include locating a conductor on a treatment area and/or a transcutaneous stimulation device relative to the first location. In addition, the method may further include adjusting how much the transcutaneous stimulation is reduced at the first location.


A proximity sensor for a transcranial magnetic stimulation (TMS) system detects the proximity of a TMS coil assembly to a position at which the coil is to receive pulses during TMS treatment and provides feedback to the operator so that the operator may adjust the TMS coil assembly to maintain optimal positioning during treatment. A flexible substrate containing a sensor or sensor array is disposed between the TMS coil assembly and the position such that the coupling of the TMS coil assembly to the position may be detected by the sensor(s). Sensor outputs are processed by signal processing circuitry to provide an indication of whether the TMS coil assembly is properly disposed with respect to the position during TMS treatment. A display provides an indication of how to adjust the TMS coil assembly to improve the positioning of the TMS coil assembly.


Patent
Neuronetics | Date: 2012-01-12

The invention is directed to a novel method for reducing discomfort caused by transcutaneous stimulation. The novel method includes providing transcutaneous stimulation, reducing the transcutaneous stimulation at a first location, and substantially maintaining the transcutaneous stimulation at a second location. The transcutaneous stimulation may be created by electric and/or magnetic fields. The first location may be relatively proximate to the cutaneous surface and may comprise tissue, nerves and muscle. Also, the second location may be relatively deeper than the first location and include, for example, brain tissue that requires the transcutaneous stimulation for treatment purposes. The invention further may include locating a conductor on a treatment area and/or a transcutaneous stimulation device relative to the first location. In addition, the method may further include adjusting how much the transcutaneous stimulation is reduced at the first location.


A proximity sensor for a transcranial magnetic stimulation (TMS) system detects the proximity of a TMS coil assembly to a position at which the coil is to receive pulses during TMS treatment and provides feedback to the operator so that the operator may adjust the TMS coil assembly to maintain optimal positioning during treatment. A flexible substrate containing a sensor or sensor array is disposed between the TMS coil assembly and the position such that the coupling of the TMS coil assembly to the position may be detected by the sensor(s). Sensor outputs are processed by signal processing circuitry to provide an indication of whether the TMS coil assembly is properly disposed with respect to the position during TMS treatment. A display provides an indication of how to adjust the TMS coil assembly to improve the positioning of the TMS coil assembly.

Loading Neuronetics collaborators
Loading Neuronetics collaborators